Anthera Pharmaceuticals Inc. (Nasdaq: ANTH) successfully completed an interim
analysis of a Phase 3 study of blisibimod in patients with Systemic
Lupus Erythematosus. The stock price gained 80 cents to $3.40.
Anthera completes interim analysis
February 10, 2015 at 12:56 PM EST
